Automate Your Wheel Strategy on XGN
With Tiblio's Option Bot, you can configure your own wheel strategy including XGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XGN
- Rev/Share 2.7916
- Book/Share 0.9975
- PB 11.8792
- Debt/Equity 0.1376
- CurrentRatio 4.9525
- ROIC -0.2788
- MktCap 260743146.0
- FreeCF/Share -0.758
- PFCF -16.3128
- PE -14.7153
- Debt/Assets 0.0493
- DivYield 0
- ROE -1.3626
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | XGN | B. Riley Securities | -- | Buy | -- | $15 | Sept. 11, 2025 |
| Upgrade | XGN | KeyBanc Capital Markets | Sector Weight | Overweight | -- | $12 | July 30, 2025 |
| Initiation | XGN | Craig Hallum | -- | Buy | -- | $12 | July 23, 2025 |
News
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
Published: October 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
Read More
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Exagen Inc. (NASDAQ:XGN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Douglas - Investors Relations Officer Conference Call Participants Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division Margarate Elizabeth Boeye - William Blair & Company L.L.C.
Read More
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Exagen Inc. (XGN) came out with a quarterly loss of $0.18 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.
Read More
Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer.
Read More
Exagen Inc. Prices Public Offering of Common Stock
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share.
Read More
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Exagen Inc. (XGN) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Read More
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan credit facility of up to $75 million, with $25 million funded at closing to retire an existing debt facility and strengthen the balance sheet.
Read More
About Exagen Inc. (XGN)
- IPO Date 2019-09-19
- Website https://www.exagen.com
- Industry Medical - Diagnostics & Research
- CEO John Aballi
- Employees 209